NCT05207111View on ClinicalTrials.gov

Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Healthy Volunteers Bioavailability Study
Interventions
DRUG

Revefenacin Inhalation Solution

Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.

Trial Locations (1)

Unknown

Xuzhou Central Hospital, Xuzhou

All Listed Sponsors
lead

Mylan Pharma UK Ltd.

INDUSTRY

NCT05207111 - Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution | Biotech Hunter | Biotech Hunter